number of weight loss drug prescriptions q3 2024 semaglutide tirzepatide vs Tirzepatide: Head-to-Head for & Diabetes Health Advances Insights :: Health
Description
Victoza (liraglutide), the first GLP-1 for type 2 diabetes to lose exclusivity in June 2024, may not generate significant savings due to its once-daily dosing and limited market share
This information is provided for educational purposes only and should not be considered medical advice
The five-role care team is genuinely more comprehensive than most competitors
Those are bold numbers
